CPE
Daniel A. Hussar, PhD, FAPhA
Part 1 (Pharmacy Today, December 2019) of this series on new FDA-approved therapeutic agents marketed in 2019 reviewed eight new therapeutic agents: omadacycline tosylate (Nuzyra—Paratek), sarecycline hydrochloride (Seysara—Almirall), lefamulin acetate (Xenleta—Nabriva), rifamycin sodium (Aemcolo—Aries), prucalopride succinate (Motegrity—Shire), romosozumab-aqqg (Evenity—Amgen), upadacitinib (Rinvoq—AbbVie), and risankizumab-rzaa (Skyrizi—AbbVie).This second part of the series reviews eight additional agents (Table 1) marketed in 2019: istradefylline (Nourianz—Kyowa Kirin), siponimod (Mayzent—Novartis), onasemnogene abeparvovec-xioi (Zolgensma—AveXis), brexanolone (Zulresso—Sage), bremelanotide acetate (Vyleesi—AMAG), solriamfetol hydrochloride (Sunosi—Jazz), pitolisant hydrochloride (Wakix—Harmony), and elexacaftor/tezacaftor/ivacaftor (Trikafta—Vertex).
Following our review of each new therapeutic agent, we compare the new drug with the older medication(s) with which it is most similar in properties and uses, and we identify advantages and disadvantages. Advantages and disadvantages are identified at the time the new drug is first marketed and do not reflect approval of additional new drugs and/or changes that occur after the drug is initially marketed.
CPE assessment
This assessment must be taken online; please see “CPE information” in the sidebar on the previous page for further instructions. The online system will present these questions in random order to help reinforce the learning opportunity. There is only one correct answer to each question.
CPE information
To obtain the 2.0 contact hours (0.2 CEUs) of CPE credit for this activity, you must complete the online assessment with a passing grade of 70% or better, complete the evaluation, and CLAIM CREDIT at http://apha.us/CPE. You will have two opportunities to successfully complete the assessment, and the questions will be in randomized order. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests.
This policy is intended to maintain the integrity of the CPE activity. Learners who successfully complete this activity by the expiration date can receive CPE credit. Please visit CPE Monitor for your statement of credit/transcript.
To claim credit
1. Go to http://apha.us/CPE.
2. Log in to your APhA account, or register as a new user.
3. Select “Enroll Now” or “Add to Cart” (click “View Cart” and “Check Out”).
4. Complete the assessment and evaluation.
5. Click “Claim Credit.” You will need to provide your NABP e-profile ID number to obtain and print your statement of credit.
Assistance is available Monday through Friday from 8:30 am to 5:00 pm ET at APhA InfoCenter by calling 800-237-APhA (2742) or by e-mailing infocenter@aphanet.org.